Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.
Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Ecstein E, Untereiner M, Vuillemin E, Merran S, Andrieu JM. Tourani JM, et al. Among authors: boaziz c. Ann Oncol. 1996 Jul;7(5):525-8. doi: 10.1093/oxfordjournals.annonc.a010644. Ann Oncol. 1996. PMID: 8839910 Free article. Clinical Trial.
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM, Jaillon-Abraham C, Lucas V, Chrétien Y, Mayeur D, Di Palma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Larregain D, Ecstein E, Untereiner M, Andrieu JM. Tourani JM, et al. Among authors: boaziz c. Bull Cancer. 1997 Apr;84(4):351-6. Bull Cancer. 1997. PMID: 9238157 Clinical Trial. French.
Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
Tourani JM, Grise P, Lucas V, Mayeur D, Dufour B, Di Palma M, Boaziz C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Untereiner M. Tourani JM, et al. Among authors: boaziz c. Cancer Biother Radiopharm. 1996 Oct;11(5):297-300. doi: 10.1089/cbr.1996.11.297. Cancer Biother Radiopharm. 1996. PMID: 10851507 Clinical Trial. No abstract available.
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Andre T, et al. Among authors: boaziz c. J Clin Oncol. 2003 Aug 1;21(15):2896-903. doi: 10.1200/JCO.2003.10.065. J Clin Oncol. 2003. PMID: 12885807 Clinical Trial.
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.
André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Billiau V, Buyse M, Gramont A; Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. André T, et al. Among authors: boaziz c. Semin Oncol. 2001 Feb;28(1 Suppl 1):35-40. doi: 10.1016/s0093-7754(01)90250-7. Semin Oncol. 2001. PMID: 11273588 Clinical Trial.
28 results